November 26, 2015
Sinclair IS Pharma going aesthetic
Sinclair IS Pharma plc will sell its non-aesthetics business to Alliance Pharma plc for £132m
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
November 26, 2015
FDA may withhold approval of Dr. Reddy’s new applications or supplements listing
The FDA said that, until Dr. Reddy’s complete all corrections and FDA confirms its compliance with CGMP, it may withhold approval of any new applications or supplements listing Dr. Reddy as a drug product or API manufacturer.
November 26, 2015
NICE recommends drugs to treat 4 different medical conditions
The National Institute for Health and Care Excellence (NICE) has published its final recommendations on whether six different drug treatments…
November 26, 2015
LEO Pharma appoints Svend Andersen EVP head of Europe+
LEO Pharma has named Svend Andersen as incoming EVP, Head of Region EUROPE+, who will assume the position of Executive Vice President, Head of Region EUROPE+, on January 1, 2016. He will join LEO Pharma’s Executive Leadership Team and report directly to the CEO.
November 26, 2015
Teva to receive global development and commercial rights to Hemtares’ novel CGRP antagonists
Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Sosei Group’s subsidiary Heptares, for the treatment of migraine.
November 26, 2015
Amgen’s first Humira biosimilar application for ABP 501 to the FDA
Amgen has filed a Biologics License Application (BLA) with the United States (U.S.) Food and Drug Administration (FDA) for ABP 501,…
November 25, 2015
Glades Drugs recalls its Vitamin D3 capsules
Glades Drugs has voluntarily recalled its Vitamin D3 capsules
November 25, 2015
Allergan settles with New York over Memantine. Agrees to pay $170K for state’s litigation expenses
Allergan has agreed with the New York State Attorney General’s Office to end the litigation under Section 2 of the Sherman Act, and other statutes with the Attorney General over the decision of Forest Laboratories
November 25, 2015
U.S. politicians slam tax-avoiding Pfizer-Allergan deal
U.S. politicians condemned Pfizer Inc’s deal with Allergan Plc as a tax dodge on Monday, bringing another round of hand-wringing in Washington over the corporate tax code, though legislative action before 2017 is unlikely.
November 25, 2015
Allergan and Rugen Therapeutics to jointly support novel therapies Autism Spectrum Disorders
Allergan plc, a company recently bought by Pfizer, and Rugen Therapeutics will jointly support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).